Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Summit Therapeutics published Phase III HARMONi trial results in The Lancet Oncology, showing ivonescimab plus chemotherapy improved PFS in EGFR-mutated NSCLC patients.
Northisle added Gerardo Fernandez as Director, Dr. Gillian Davidson as Strategic Advisor, and Maurice Tagami as Process Design and Metallurgical Advisor.
SCHMID Group N.V. reported H1 2026 revenues of €46.0 million, up from €16.9 million in the same period last year, with China contributing over half of the revenues.
